ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders |
At the 2017 annual meeting of stockholders (the Annual Meeting)
of Aldeyra Therapeutics, Inc. (the Company) held on June8, 2017,
the following proposals were submitted to the stockholders of the
Company:
| Proposal1: |
The election of two directors to serve as ClassIII directors until the Companys 2020 annual meeting of stockholders or until their successors are duly elected and qualified. |
| Proposal2: |
The ratification of the appointment of BDO USA, LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017. |
For more information about the foregoing proposals, see the
Companys definitive proxy statement on Schedule 14A filed with
the United States Securities and Exchange Commission on April24,
2017 (the Proxy Statement). Of the 15,131,880 shares of the
Companys common stock entitled to vote at the Annual Meeting,
11,622,334 shares, or approximately 76.8%, were represented at
the meeting in person or by proxy, constituting a quorum. The
number of votes cast for, against or withheld, as well as
abstentions and broker non-votes, if applicable, in respect of
each such proposal is set forth below:
| Proposal1: | Election of Directors. |
The Companys stockholders elected the following directors to
serve as ClassIII directors until the 2020 annual meeting of
stockholders or until their successors are duly elected and
qualified. The votes regarding the election of the directors were
as follows:
|
Director |
VotesFor | VotesWithheld | BrokerNon-Votes | |||||||||
|
Todd C. Brady, M.D., Ph.D. |
9,496,881 | 12,030 | 2,113,423 | |||||||||
|
Martin J. Joyce |
9,504,881 | 4,030 | 2,113,423 |
| Proposal2: | Ratification of Appointment of BDO USA, LLP. |
The Companys stockholders ratified the appointment of BDO USA,
LLP as the Companys independent registered public accounting firm
for the fiscal year ending December31, 2017. The votes regarding
this proposal were as follows:
|
Votes For |
VotesAgainst |
VotesAbstaining |
BrokerNon-Votes |
|||
|
11,611,592 |
1,296 | 9,446 |
About ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
